Thyrotropin Regulates IL-6 Expression in CD34+ Fibrocytes: Clear Delineation of Its cAMP-Independent Actions

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Raychaudhuri, Nupur ^a   Fernando, Roshini ^a   Smith, Terry J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C BETA II; PROTEIN KINASE C MU; RNA; THYROTROPIN; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CD34+ FIBROCYTE; CONCENTRATION (PARAMETERS); CONNECTIVE TISSUE CELL; ENDOCRINE OPHTHALMOPATHY; GENE; GENE INDUCTION; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IL 6 GENE; IMMUNOREGULATION; MOLECULAR MECHANICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA STABILITY; SIGNAL TRANSDUCTION; SYNDROME DELINEATION; TRANSCRIPTION REGULATION; UPREGULATION;

ANTIGENS, CD34; BLOTTING, WESTERN; CYCLIC AMP; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; INTERLEUKIN-6; MUTAGENESIS, SITE-DIRECTED; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; THYROTROPIN;

EID: 84884552072     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075100     Document Type: Article

References (84)

1. Szkudlinski MW, Fremont V, Ronin C, Weintraub BD, (2002) Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev 82: 473-502.
2. Parmentier M, Libert F, Maenhaut C, Lefort A, Gerard C, et al. (1989) Molecular cloning of the thyrotopin receptor. Science 246: 1620-1622.
3. Vassart G, Dumont JE, (1992) The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocrine Rev 13: 96-611.
4. Endo T, Ohta K, Haraguchi K, Onaya T, (1995) Cloning and functional expression of a thyrotropin receptor cDNA from rat fat cells. J Biol Chem 270: 10833-10837.
5. Bell A, Gagnon A, Grunder L, Parikh SJ, Smith TJ, et al. (2000) Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. Am J Physiol (Cell Physiol) 279: C335-C340.
6. Klein JR, (2003) Physiological relevance of thyroid stimulating hormone and thyroid stimulating hormone receptor in tissues other than the thyroid. Autoimmunity 36: 417-421.
7. Davies TF, Teng CS, McLachlan SM, Smith BR, Hall R, (1978) Thyrotropin receptors in adipose tissue, retro-orbital tissue and lymphocytes. Mol Cell Endocrinol 9: 303-310.
8. Heufelder AE, Dutton CM, Sarkar G, Donovan KA, Bahn RS, (1993) Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy. Thyroid 3: 297-300.
9. Paschke R, Metcalfe A, Alcalde L, Vassart G, Weetman A, et al. (1994) Presence of nonfunctional thyrotropin receptor variant transcripts in retroocular and other tissues. J Clin Endocrinol Metab 79: 1234-1238.
10. Marcus C, Ehren H, Bolme P, Arner P, (1988) Regulation of lipolysis during the neonatal period. Importance of thyrotropin. J Clin Invest 82: 1793-1797.
11. Brent GA, (2008) Graves' disease. N Engl J Med 358: 2594-2605.
12. Zakarija M, McKenzie JM, (1987) The spectrum and significance of autoantibodies reacting with the thyrotropin receptor. Endocrinol Metab Clin North Am 16: 343-363.
13. Zakarija M, Jin S, McKenzie JM, (1988) Evidence supporting the identity in Graves' disease of thyroid-stimulating antibody and thyroid growth-promoting immunoglobulin G as assayed in FRTL5 cells. J Clin Invest81: 879-884.
14. Davies TF, Ando T, Lin RY, Tomer Y, Latif R, (2005) Thyrotropin receptor-associated diseases: from adenomata to Graves' disease. J Clin Invest 115: 1972-1983.
15. Kazim M, Goldberg RA, Smith TJ, (2002) Insights into the pathogenesis of thyroid-associated orbitopathy. Evolving rationale for therapy. Arch Ophthalmol 120: 380-386.
16. Grubeck-Loebenstein B, Trieb K, Sztankay A, Holter W, Anderl H, et al. (1994) Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. J Clin Invest 93: 2738-2743.
17. Jaume JC, Portolano S, Prummel MF, McLachlan SM, Rapoport B, (1994) Molecular cloning and characterization of genes for antibodies generated by orbital tissue-infiltrating B-cells in Graves' ophthalmopathy. J Clin Endocrinol Metab 78: 348-352.
18. De'Carli M, D'Elios MM, Mariotti S, Marcocci C, Pinchera A, et al. (1993) Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab. 77: 1120-1124.
19. Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, et al. (1996) Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab 81: 2976-2979.
20. Taga T, Kishimoto T, (1997) GP130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15: 797-819.
21. Hirano T (1998) Interleukin 6 and its receptor: ten years later. Int Rev Immunol 16, 249-284.
22. Muraguchi A, Kishimoto T, Miki Y, Kuritani T, Kaieda T, et al. (1981) T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 127: 412-416.
23. Miyazawa K, Mori A, Miyata H, Akahane M, et al. (1998) Regulation of interleukin-1β-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. J Biol Chem 273: 24832-24838.
24. Brown CY, Lagnade CA, Goodall GJ, (1996) A cytokine mRNA-destabilizing element that is structurally and functionally distinct from A+U-rich elements. Proc Natl Acad Sci USA 93: 13721-13725.
25. Grubeck-loebenstein B, Buchan G, Chantry D, Kassal H, Londei M, et al. (1989) Analysis of intrathyroidal cytokine production in thyroid autoimmune disease: thyroid follicular cells produce interleukin-1 alpha and interleukin-6. Clin Exp Immunol 77: 324-30.
26. Antunes T, Gagnon A, Bell A, Sorisky A, (2005) Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. Obesity Res 13: 2066-2071.
27. Bell A, Gagnon A Sorisky A, (2003) TSH stimulates IL-6 secretion from adipocytes in culture. Arterioscler Thromb Vasc Biol 23: e65-e66.
28. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A, (1994) Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1: 71-81.
29. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN, (2001) Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166: 7556-7562.
30. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, et al. (2004) Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114: 438-446.
31. Chesney J, Bacher M, Bender A, Bucala R, (1997) The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci USA (94) (): 6307-6312.
32. Pilling D, Fan T, Huang D, Kaul B, Gomer RH, (2009) Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblast. PLoS One 4: 7475.
33. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S, (2003) Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 171: 380-389.
34. Douglas RS, Afifiyan NF, Hwang CJ, Chong K, Haider U, et al. (2010) Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 95: 430-438.
35. Smith TJ, Padovani-Claudio DA, Lu Y, Raychaudhuri N, Fernando R, et al. (2011) Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease. J Clin Endocrinol Metab 96: 3827-3837.
36. Fernando R, Atkins S, Raychaudhuri N, Lu Y, Li B, et al. (2012) Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proc Natl Acad Sci U S A. 109: 7427-7432.
37. Gillespie EF, Papageorgiou KI, Fernando R, Raychaudhuri N, Cockerham KP, et al. (2012) Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab 97: E740-E746.
38. Smith TJ, Sempowski GD, Wang HS, Del Vecchio PJ, Lippe SD, et al. (1995) Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts. J Clin Endocrinol Metab 80: 2620-2625.
39. Sunthornthepvarakul T, Gottschalk ME, Hayashi Y, Refetoff S, (2004) Brief report: resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene. N Engl J Med 332: 155-160.
40. Davidson LA, Aymond CM, Jiang YH, Turner ND, Lupton JR, et al. (1998) Non-invasive detection of fecal protein kinase C βII and ζ messenger RNA; putative biomarkers for colon cancer. Carcinogenesis 19: 253-257.
41. Cheng L, Pricolo V, Biancani P, Behar J, (2008) Overexpression of progesterone receptor B increases sensitivity of human colon muscle cells of progesterone. Am J Physiol Gastrointest Liver Physiol 295: G493-G502.
42. Freson K, Thys C, Wittevrongel C, Proesmans W, Hoylaerts MF, et al. (2002) Pseudohypoparathyroidism type IB with disturbed imprinting in the GNAS1 cluster and Gsa deficiency in platelets. Hum Mol Genet 11: 2741-2750.
43. Chen B, Tsui S, Smith TJ, (2005) IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol 15: 1310-1319.
44. Dreyer C, Hausen P, (1978) Inhibition of mammalian RNA polymerase by 5,6 dichlororibofuranosylbenzimidazole (DRB) and DRB triphosphate. Nucleic Acids Res 5: 3325-3335.
45. Kero J, Ahmed K, Wettschureck N, Tunaru S, Wintermantel T, et al. (2007) Thyrocyte-specific Gq/G11 deficiency impairs thyroid function and prevents goiter development. J Clin Invest 117: 2399-407.
46. Raychaudhuri N, Douglas RS, Smith TJ, (2010) PGE2 induces IL-6 in orbital fibroblasts through EP2 receptors and increased gene promoter activity: implications to thyroid-associated ophthalmopathy. PLoS One 5: e15296.
47. Botelho LH, Rothermel JD, Coombs RV, Jastorff B, (1988) cAMP analog antagonists of cAMP action. Meth Enzymol 159: 159-172.
48. Zaballos MA, Garcia B, Santisteban P, (2008) Gβγ dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cells. Mol Endocrinol 22: 1183-1199.
49. Lankov I, Praskova M, Kalenderova S, Tencheva Z, Mitov I, et al. (2002) The effect of chemical blockade of PKC with Gö6976 and Gö6983 on proliferation and MAPK activity in IL-6-dependent plasmacytoma cells. Leukemia Res 26: 363-368.
50. Sanders JL, Stern PH, (2000) Protein kinase C involvement in interleukin-6 production by parathyroid hormone and tumor necrosis factor-α in UMR-106 osteoblastic cells. J Bone Miner Res 15: 885-893.
51. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, et al. (1991) The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 266: 15771-15781.
52. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P, (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol 7: 261-9.
53. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, et al. (1998) Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281: 2042-5.
54. Zhu J, Huang JW, Tseng PH, Fowble J, Shiau CW, et al. (2004) From the Cyclooxygenase-2 inhibitor Celecoxib to a novel class of 3-Phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Research 64: 4309-4318.
55. Woloshin RI, Walton KM, Rehfuss RP, Goodman RH, Cone RD, (1992) 3′,5′- Cyclic adenosine monophosphate-regulated enhancer binding (CREB) activity is required for normal growth and differentiated phenotype in the FRTL5 thyroid follicular cell line. Mol Endocrinol 6: 1725-1733.
56. Nguyen LQ, Kopp P, Martinson F, Stanfield K, Roth SI, et al. (2000) A dominant negative CREB (cAMP response element-binding protein) isoform inhibits thyrocyte growth, thyroid-specific gene expression, differentiation, and function. Mol Endocrinol 14: 1448-1461.
57. Morshed SA, Latif R, Davies TF, (2009) Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 150: 519-529.
58. Tayze T, Antunes AG, Langille ML, Sorisky A, (2008) Thyroid-stimulating hormone induces Interleukin-6 release from human adipocytes through activation of the nuclear factor-κB pathway. Endocrinology 149: 3062-3066.
59. Du K, Montimony M, (1998) CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273: 32377-32379.
60. Tsui S, Naik N, Hoa N, Hwang C J, Afifiyan NF, et al. (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol 181: 4397-4405.
61. Porcellini A, Messina S, De Gregorio G, Feliciello A, Carlucci A, et al. (2003) The expression of the thyroid-stimulating hormone (TSH) receptor and the cAMP-dependent protein kinase RII beta regulatory subunit confers TSH-cAMP-dependent growth to mouse fibroblasts. J Biol Chem 278: 40621-40630.
62. Hara T, Namba H, Takamura N, Yang TT, NagayamaY, et al, (1999) Thyrotropin regulates c-Jun N-terminal kinase (JNK) activity through two distinct signal pathways in human thyroid cells. Endocrinology 140: 1724-1730.
63. Pham N, Cheglakov I, Koch CA, de Hoog CL, Moran MF, et al. (2000) The guanine nucleotide exchange factor CNrasGEF activates Ras in response to cAMP and cGMP. Current Biology 10: R577-R580.
64. Tsygankova OM, Saavedra A, Rebhun JF, Quilliam LA, Meinkoth JL, (2001) Coordinated regulation of Rap1 and thyroid differentiation by cyclic AMP and protein kinase A. Mol Cell Biol. 21: 1921-1929.
65. Saunier B, Pierre M, Jacquemin C, Courtin F, (1993) Evidence for cAMP-independent thyrotropin effects on astroglial cells. Eur J Biochem 218: 1091-1094.
66. Saunier B, Tournier C, Jacquemin C, Pierre M, (1995) Stimulation of mitogen-activated protein kinase by thyrotropin in primary cultured human thyroid follicles. J Biol Chem 270: 3693-3697.
67. Johannes F, Prestle J, Eis S, Oberhangenamm P, Pfizenmaier K, (1994) PKCμ is a novel, atypical member of the protein kinase C family. J Biol Chem 269: 6140-6148.
68. Nishikawa K, Toker A, Johannes FJ, Songyang Z, Cantley L, (1997) Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem 272: 952-960.
69. Reyland M, (2009) Protein kinase C: multi-functional regulators of cell life and death. Front Biosci 14: 2386-2399.
70. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, et al. (1997) Expression of protein kinase c beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 100: 2189-2195.
71. Sledge G W, Gokmen-Polar Y, (2006) Protein kinase C-beta as a therapeutic target in breast cancer. Semin Oncol 33: S15-S18.
72. Martiny-Baron G, Fabbro D (2007) Classical PKC isoforms in cancer. Pharm Res 55, 477-486.
73. Konopatskaya O, Matthews AS, Matthew TH, Gilio K, Cosemans JM, et al. (2011) Protein kinase C mediates platelet secretion and thrombus formation through protein kinase D2. Blood. 118: 416-424.
74. Naka T, Nishimoto N, Kishimoto T, (2002) The paradigm of IL-6: from basic science to medicine. Arthritis Res 4: S233-S242.
75. Grassl C, Bruno L, Detlef S, Ulrich D, (1999) Transcriptional regulation of the interleukin-6 gene in messengial cells. J Am Soc Nephrol 10: 1466-1477.
76. Legrand-Poels D, Schoonbroodt S, Piette J, (2000) Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem J 349: 765-773.
77. Motomura T, Kasayama S, Takagi M, Kurebayashi S, Matsui H, et al. (1998) Increased interleukin-6 production in mouse osteoblastic MC3T3-E1 cells expressing activating mutant of the stimulatory G protein. J Bone Miner Res 13: 1084-1091.
78. Sehgal PB, (1992) Regulation of IL6 gene expression. Res Immunol 143: 724-734.
79. Martin CA, Dorf ME, (1991) Differential regulation of interleukin-6, macrophage inflammatory protein-1, and JE/MCP-1 cytokine expression in macrophage cell-lines. CellImmunol 135: 245-258.
80. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J, (1995) Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162: 248-255.
81. Ishihara K, Hirano T, (2002) IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13: 357-368.
82. Salvi M, Pedrazzoni M, Girasole G, Guiliani N, Minelli R, et al. (2000) Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 143: 197-202.
83. Molnár I, Balázs C, (1997) High circulating IL-6 level in Graves' ophthalmopathy. Autoimmunity 25: 91-96.
84. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, et al. (2000) Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 85: 1194-1199.